Mostrando 10 resultados de: 10
Filtros aplicados
Subtipo de publicación
Article(10)
Publisher
Bionatura(4)
Cancer Biology and Therapy(2)
Clinical Cancer Research(1)
Frontiers in Pharmacology(1)
Human Vaccines(1)
Origen
google(1)
1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients
ArticleAbstract: Conventional treatment of non-small cell lung cancer (NSCLC) has apparently reached a plateau of effPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Aguirre F., Alfonso S., Alonso D.F., Barroso M.C., Carmen Elena Viada, De La Torre A.V., Díaz R.M., Gabri M.R., Gómez R., Hernández A.M., Macías A.E., Pérez K., Pérez R., Rodríguez J., Santiesteban E.R., Suárez E., Toledo D., Vázquez A.M.Fuentes:scopusA randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients
ArticleAbstract: Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated gangliPalabras claves:Autores:Alfonso S., Areces F., Carmen Elena Viada, Cepeda M., Chong E., De La Torre A.V., Flores Y.I., García E., Gonzalez Z., Guerra P.P., Hernández A.M., Hernández M., Macías A.E., Mazorra Z., Mendoza I.C., Ortiz R.A., Pérez K., Pérez R., Santiesteban E.R., Tania Crombet, Toledo D., Valdes-Zayas A., Vázquez A.M.Fuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusEvaluation of racotumomab for the treatment of lung cancer: Meta-analysis of controlled trials of the CIM
ArticleAbstract: Racotumomab is a therapeutic cancer vaccine entirely developed in Cuba and licensed in the country fPalabras claves:immunotherapy, Non-small cell lung cancer, Oncological vaccines, Racotumomab, Vaccinal treatmentAutores:Alfonso S., Aliuska Frías, Ballesteros J., Carmen Elena Viada, Hernández M., Mabel Álvarez, Macías A.E., Martha M. Fors-López, Quintero J., Robaina M.Fuentes:scopusNimotuzumab for the treatment of patients with malignant glioma. Comparison between pre-registration and post-approved studies
ArticleAbstract: Nimotuzumab is a monoclonal antibody targeted against the epidermal growth factor receptor approvedPalabras claves:And High-grade glioma, Controlled clinical studies, nimotuzumab, Postmarking studies, Target therapiesAutores:Aliuska Frías, Carmen Elena Viada, García L., Luaces P.L.o., Mabel Álvarez, Macías A.E., Santiesteban Y., Saurez G., Tania CrombetFuentes:scopusImmunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients
ArticleAbstract: Increased levels of NeuGc-containing gangliosides have been described in human breast cancer. A contPalabras claves:Breast Cancer, cancer vaccine, Clinical trial, Ganglioside, immunotherapy, NeuGcGM3, patientsAutores:Cardoso J., Carmen Elena Viada, Carr A., De La Torre A.V., Díaz R., Fernandez L.E., Macías A.E., Marinello P., Mazorra Z., Mulens V., O'Farrill M., Pérez R., Rodríguez R., Saurez G., Tania CrombetFuentes:scopusSafety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: A dose-escalation phase I study trial
ArticleAbstract: Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effectivPalabras claves:Human epidermal growth factor receptor, Immunogenicity, Prostate cancer, safety, Therapeutic vaccineAutores:Aira L.E., Bárbara Wilkinson, Caballero I., Casacó Parada A.R., Coba K., González J.G., González N., Lavastida A., Luaces P.L.o., Macías A.E., Mazorra Z., Mesa M., Popa X., Rivero J., Sanchez B., Santiesteban Y., Suárez E., Tania Crombet, Troche M.Fuentes:scopusSafety of racotumomab in the treatment of patients with non-small cell lung cancer
ArticleAbstract: In Cuba, lung cancer ranks second in incidence and first in mortality. Therefore, it is necessary toPalabras claves:Adverse events, Clinical trial, Non-small cell lung cancer, RacotumomabAutores:Carmen Elena Viada, Estevez D., Gastón Y., Macías A.E., Pérez Ruiz L.Fuentes:scopusSecurity 1E10 anti-idiotypic vaccine in patients with tumors of different locations
ArticleAbstract: Cancer is a leading cause of death in Cuba and the world. Lung cancer is the leading cause of death,Palabras claves:Anti-idiotypic, Breast, Cáncer, COLON, Non-small cell lung vaccine, security, Small cell lungAutores:Alfonso S., Carmen Elena Viada, García E., Guerra P.P., Hernández M., Macías A.E., MARTHA FORS, Martha M. Fors-López, Mendoza I.C., Neninger Vinageras E., Pérez Ruiz L., Santiesteban E.R., Vázquez A.M.Fuentes:googlescopusSystemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab
ArticleAbstract: Nimotuzumab (h-R3) is a humanized anti-epidermal growth factor receptor monoclonal antibody (mAb) rePalabras claves:animal model, CETUXIMAB, Epidermal growth factor receptor, General toxicity, H-R3, Monkeys, nimotuzumab, Skin toxicityAutores:Arteaga M.E., Ballester-Labrada A., Baro F., Boleda M., Casacó Parada A.R., Charro L., Fuentes D., García M., González B., González C., Hernández O., Ledón N., Macías A.E., Morales Y., Orphee R., Pardo B., Pérez A., Ramos M., Rodríguez V., Rodriquez L., Subirós N., Tania Crombet, Viña L.Fuentes:scopus